For US$323M, Samsung Biologics Buys Land For A Second Manufacturing Campus In South Korea

By Kevin Dunleavy

Samsung’s expansion plan for its CDMO unit is an efficient, no-nonsense enterprise, marching on with no end in sight.

Maybe that’s why at its home base in South Korea, Samsung Biologics refers to its factories by number. Just 11 years into its existence, Samsung has Plants 1, 2 and 3 in operation, Plant 4 under construction, and Plants 5 and 6 are on the drawing board.

On Monday, Samsung revealed that it has acquired additional land in Incheon on which to construct its new duplicate facility, Bio Campus II. The parcel was purchased for 426 billion won (US$323 million) and is 30 per cent larger than Samsung’s original campus.